Liotta, D; Schinazi, R
In 2002, Emory licensed its rights to elvucitabine to Achillion Pharmaceuticals, Inc. Elvucitabine is an L-cytosine nucleoside analog with potent in vitro activity against wild-type strains of human immunodeficiency virus (HIV), as well as strains of HIV that are resistant to certain currently used therapies. Achillion has completed clinical studies evaluating the use of elvucitabine in patients chronically infected with HIV. In these studies, elvucitabine demonstrated potent anti-HIV activity in patients whose virus carries the M184V mutation, a mutation associated with lamivudine (3TC) resistance. In 2011, Achillion partnered with GCA Therapeutics, Ltd. (GCAT) and its Chinese joint venture with Tianjing Institute of Pharmaceutical Research to clinically develop and commercialize elvucitabine in China, Hong Kong, and Taiwan. Under the collaboration, GCAT, with its Chinese joint venture with Tianjing Institute of Pharmaceutical Research (TIPR), will assume all development and regulatory responsibility and associated costs for elvucitabine.